All News

The ivonescimab-based regimen appeared effective in both platinum-sensitive and platinum-resistant cohorts in a phase 2 study.

Giredestrant plus palbociclib improved PFS numerically but not significantly vs letrozole plus palbociclib in 1L ER+, HER2– mBC.

Findings from the I-SPY 2.2 trial may show an important step toward treatment de-escalation for certain patients with HER2-negative breast cancer.

Grade 3 or higher TRAEs occurred in 73.7% of patients with HCC who received camrelizumab plus rivoceranib and TACE vs 28.7% who received TACE alone.

Data from the VIKTORIA-1 trial support the PAM pathway as a molecular driver in HR-positive, HER2-negative breast cancer of any PIK3CA mutation status.

Data from the PANKU-Breast02 trial may support iza-bren as a new standard of care in this TNBC population.

More than 90% of patients achieved a composite complete response to azacitidine plus venetoclax and ivosidenib in a phase 1b/2 trial.

Modulation of angiogenic and immune-related pathways in ccRCC might provide rationale for checkpoint- or VEGFR-TKI–based combinations with HC-7366.

The nilotinib tablets may support patients who have difficulty swallowing while offering flexibility to take treatment with or without water.

Results from cohort C of the TRASTS study showed trabectedin/radiotherapy had positive response rates for patients with resectable retroperitoneal L-sarcomas.

Findings from the OptimUM-02 trial may support a new potential therapeutic standard for patients with HLA-A*02:01–negative metastatic uveal melanoma.

Atebimetinib plus modified gemcitabine/nab-paclitaxel demonstrated an ORR of 36% and median OS of 17.3 months in first-line metastatic pancreatic cancer.

The hypofractionated radiotherapy schedule was noninferior to the standard fractionation schedule regarding HRQOL for patients with cervical cancer.

Fedratinib may target various proliferative pathways in MDS/MPN that other current standards of care miss, according to Andrew Kuykendall, MD.

For patients with early breast cancer receiving chemotherapy, the use of a dexamethasone mouthwash did not significantly reduce the incidence of oral mucositis.

The FLAME trial showed osimertinib plus carboplatin/pemetrexed significantly improved PFS vs osimertinib monotherapy in ctDNA-persistent EGFR-mutant NSCLC.

The role of adjuvant immunotherapy remains unclear in this NSCLC population following data from the phase 3 ALCHEMIST trial.

Final analysis of KEYNOTE-522 confirms pembrolizumab plus chemotherapy improves event-free and overall survival in high-risk early-stage TNBC.

Cost-utility analysis of the CHALLENGE trial showed structured exercise following adjuvant chemotherapy for colon cancer is cost-saving and improves QALYs.

Patients with positive images may benefit from additional therapy not directed at the androgen receptor; however, prospective validation is required.

Findings from a study exploring how AI-driven NCCN guideline interpretation can optimize genetic testing and reduce clinician burden in prostate cancer.

Seven-year data from the CROWN study show improved PFS with lorlatinib over crizotinib among patients with ALK-positive non–small cell lung cancer.

A matching-adjusted indirect comparison highlighted linvoseltamab as a potentially effective treatment option for those with triple-class–exposed disease.

Neoadjuvant ipilimumab plus nivolumab and relatlimab achieved a major pathologic response in 73.7% of patients with resectable stage III/IV melanoma.

Data from the KEYNOTE-942 trial confirmed a durable benefit with intismeran plus pembrolizumab among patients with high-risk melanoma.

Data from the EMERALD-3 trial may position the STRIDE regimen with or without lenvatinib as a compelling therapeutic option in this HCC population.

The phase 3 HARMONi-6 trial showed ivonescimab plus chemotherapy significantly improved OS vs tislelizumab plus chemotherapy in advanced squamous NSCLC.

Nathan Goodyear, MD, discussed how prescribing exercise may enhance the efficacy of standard oncologic regimens for patients with cancer.

A second expansion phase assessing HC-7366/belzutifan in locally advanced/metastatic renal cell carcinoma is ongoing.

In 897 patients with advanced melanoma treated with ICI, conditional 5-year PFS rose from 29% at baseline to 91% for those progression-free at 4 years.